title: [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
abstract: It has been recognized that deranged mineral metabolism in CKD results not only in bone diseases but also in a higher risk of mortality, Accordingly, instead of the classic term "Renal Osteodystrophy (ROD) , "a new term, "CKD-Mineral and Bone Disorders (CKD-MBD), "has recently been proposed as a systemic disorder, with cardiovascular disease, fractures, and mortality as major outcomes. The Japanese Society for Dialysis Therapy (JSDT) clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in 2006. Then, new therapeutic modalities including cinacalcet and lanthanum carbonate have recently been introduced into the Japanese market, after JSDT guideline was published. Now, the revised version of the guideline has been prepared.
authors.affiliation: Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine.
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
mesh_terms: D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D002908:Chronic Disease; D000069449:Cinacalcet; D003956:Dialysis; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D007811:Lanthanum / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
chemical_list: D009281:Naphthalenes; C119467:lanthanum carbonate; D007811:Lanthanum; D000069449:Cinacalcet